Reply from authors re: Christopher R. Chapple. Finding the correct starting dose for OnabotulinumtoxinA. Eur Urol 2012;61:530-2

摘要

The editorial comment submitted by Chappie [1] is of great value, and we thank him for this. OnabotulinumtoxinA (ObTA) seems destined to become one of the new treatments for non-neurogenic (idiopathic) refractory overactive bladder (OAB). The risks and benefits are clearly demonstrated through the results of our work [2] and through the recent studies described by Chappie that focus on finding the optimal dosage, with a clear trend to reducing the dose in comparison with patients with neurogenic detrusor overac-tivity (NDO) [3-5]. The issue of defining clinically significant residual urine and urinary tract infection (UTI) has not been solved at this time.The development of new minimally invasive treatments with specific modes of action allows us to question whether we are able to select the best treatment for the best patient.